Exposure of cumulative atherogenic index of plasma and the development of prediabetes in middle-aged and elderly individuals: evidence from the China Health and Retirement Longitudinal Study (CHARLS) cohort study
Authors' conclusion
CumAIP is closely associated with the development of prediabetes. High CumAIP exposure not only increases the risk of prediabetes progression but also hinders its regression within a certain range. These findings suggest that monitoring and maintaining appropriate AIP levels may help prevent the deterioration of blood glucose levels.
Study context
- Population
- Middle-aged and elderly adults with prediabetes from wave 1 of the China Health and Retirement Longitudinal Study (CHARLS)
- Participants
- 2,939 participants
- Exposure
- Cumulative atherogenic index of plasma (CumAIP) quartiles
- Outcome
- Development of prediabetes: progression to diabetes and regression to normal fasting glucose (NFG)
- Follow-up
- Third wave; median 3 years
Methodological detailsmultivariable Cox regression, restricted cubic spline regression
- Multivariable Cox regression
- Restricted cubic spline regression
Main finding
As reported in the abstract
Progression to diabetes, by CumAIP quartile · median follow-up 3 years
- Overall progression to diabetes
- 15.21%
Observational data: associations, not effects.
Further findings
Regression to NFG, by CumAIP quartile · median follow-up 3 years
- Regression to normal fasting glucose (NFG), by CumAIP quartile — Overall regression to NFG
- 22.12%
Regression to NFG, by CumAIP quartile · median follow-up 3 years
- Multivariable-adjusted Cox regression: significant negative linear correlation between CumAIP and prediabetes regression
CumAIP-related diabetes risk, stratified by marital status
- Unmarried (separated, divorced, widowed or never married) had relatively higher risk of CumAIP-related diabetes than married
- Stratified analysis
Original publication
Exposure of cumulative atherogenic index of plasma and the development of prediabetes in middle-aged and elderly individuals: evidence from the CHARLS cohort study. Cardiovasc Diabetol. Published 30 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →